Ainos Inc Stock Price, News & Analysis

Ainos (NASDAQ:AIMD) has received approval from Taiwan's Food and Drug Administration (TFDA) to initiate a clinical study for its drug candidate VELDONA® in treating primary Sjögren's syndrome (pSS). The open-label study will commence at Taipei Medical University-Shuang Ho Hospital in October 2025, with completion expected in H1 2027.

VELDONA®, a low-dose oral interferon-alpha drug, has previously demonstrated significant efficacy in three large U.S. clinical trials involving 497 patients, with 300 receiving VELDONA® treatment. The drug showed notable improvement in dryness-related symptoms without serious adverse events.

Primary Sjögren's syndrome affects between 400,000 and 3.1 million people globally, with no FDA-approved therapies currently available for this chronic autoimmune disorder.

Ainos (NASDAQ:AIMD) received recognition from Water Tower Research for its AI Nose platform, an advanced smell digitization technology. The platform demonstrates impressive accuracy rates: 90+% in distinguishing everyday scents, 85% in senior care environments, and 80% across 22 industrial scent types in semiconductor settings.

Built on over a decade of innovation, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays. The technology utilizes a smell language model (SLM) that improves with continuous use, creating a data-driven flywheel effect. The company is pursuing strategic partnerships, particularly in Asia, to accelerate commercialization across healthcare, industrial, and robotics markets.

Ainos (NASDAQ:AIMD) has announced a groundbreaking partnership with ugo Inc. to launch the world's first AI Nose-enabled service robots across seven pilot sites in Japan. The robots will be deployed in pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants.

The AI Nose technology has demonstrated impressive accuracy rates: 80% accuracy across 22 industrial scent types in semiconductor facilities, 85% accuracy in senior care pilots, and over 90% accuracy in food and beverage testing. The company plans to deploy approximately 1,400 AI Nose units with ASE and expand to 5,000 units in Phase 1.

This initiative is part of Ainos' 90-day action plan and positions the company for a global SmellTech-as-a-Service rollout in 2026. The global electronic nose market is projected to grow from $29.79 billion in 2025 to $76.45 billion by 2032.

Ainos (NASDAQ:AIMD) has regained Nasdaq compliance and unveiled its 90-day roadmap for scaling its AI Nose platform. The company reported significant achievements, including a 412% year-over-year revenue increase in Q1 2025 and strategic partnerships with major industry players like ASE Technology Holding for deploying up to 15,000 AI Nose units.

The company's proprietary smell language model (SLM) has achieved 90% accuracy in classifying everyday scents, while its senior care program improved to 85% accuracy. Key partnerships with Kenmec and Solomon aim to integrate AI-powered scent intelligence into smart factory systems. The company also completed the first-ever integration of AI Nose with a humanoid robot through ugo Inc.

Ainos's 90-day plan focuses on deploying 1,400 AI Nose units with ASEH, expanding to 5,000 units, and launching SmellTech-as-a-Service (SaaS) as a subscription-based revenue model.

Ainos (NASDAQ:AIMD) received a new Water Tower Research report highlighting the company's commercial advancement in industrial AI through its AI Nose technology. The report spotlights several high-impact partnerships that position Ainos' digital olfaction platform for significant market expansion.

Key partnerships include: ASE Technology Holding, planning to deploy up to 15,000 AI Nose units; Kenmec, manufacturing and deploying AI Nose across infrastructure applications; and Solomon Technology, with a five-year agreement integrating AI Nose into Asia's manufacturing sectors. The company's smell language model (SLM) technology is set for scaled pilot programs in H2 2025, with potential multi-million-dollar recurring revenues through a SmellTech-as-a-Service subscription model starting 2026.

Ainos (NASDAQ:AIMD) has announced a strategic five-year distribution partnership with Solomon Technology Corporation to expand its AI Nose platform across Asia's industrial sectors. The partnership combines Ainos' smell language model (SLM) with Solomon's Visual Language Model (VLM) to create an advanced sensory intelligence platform.

The collaboration targets key manufacturing sectors including semiconductors, petrochemicals, autonomous mobile robots (AMRs), and healthcare. This expansion builds on Ainos' existing partnerships with ASE, Kenmec, and ugo. The global electronic nose market is projected to grow from $29.8B in 2025 to $76.5B by 2032, with Asia controlling over 70% of global semiconductor capacity and 45% of electronics manufacturing services.

Ainos (NASDAQ:AIMD) has completed a 1-for-5 stock consolidation effective June 30, 2025, while announcing significant progress in its AI-powered olfactory intelligence business. The company is targeting the electronic nose market, projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032.

The company has established key partnerships for AI Nose deployment: ASE Technology Holding (planning deployment of 1,400 units in pilot phase, scaling to 5,000 in Phase 1 and 15,000 in Phase 2), Kenmec Mechanical Engineering for smart factory integration, and ugo for robotics applications in Japan. In Q1 2025, Ainos reported a 412% year-over-year revenue growth.

The company's Smell Language Model (SLM) has achieved over 90% accuracy in classifying meat, food, and beverage samples. In the senior care sector, their technology demonstrated 85%+ accuracy in hygiene detection across 2,000+ samples. Additionally, Ainos is advancing clinical trials for VELDONA® in Taiwan for HIV-related oral warts and Sjögren's syndrome.

Ainos (NASDAQ:AIMD) has expanded its strategic partnership with ASE Technology Holding (NYSE:ASX) to deploy up to 15,000 AI Nose units across ASE's global manufacturing network. The multi-phase rollout plan includes an evaluation phase with 1,400 units, Phase 1 with 5,000 units, and Phase 2 targeting up to 15,000 units.

The AI Nose platform will be used for real-time VOC anomaly detection, cleanroom environmental sensing, and automated ESG compliance monitoring. The partnership aims to advance smart factory transformation and environmental monitoring in semiconductor operations, with Ainos expecting to generate multi-million annual recurring revenue in the coming years.

Ainos (NASDAQ:AIMD) announced a 1-for-5 stock consolidation effective June 30, 2025, aimed at attracting institutional investors and maintaining Nasdaq listing compliance. The consolidation will automatically convert every 5 shares into 1 share, with fractional shares paid in cash.

The company is entering a commercial execution phase in 2H 2025, focusing on two main verticals: AI Nose, an AI-powered scent digitization platform entering scaled field testing across senior care, robotics, and semiconductor manufacturing, and VELDONA®, a low-dose oral interferon in clinical development for both human and veterinary applications including feline chronic gingivostomatitis, Sjögren's syndrome, and HIV-related oral warts.